

# Members Obtain Free CE Credits from JCP Articles!



## ***Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations***

October 2020 – *The Journal of Clinical Pharmacology* (JCP)

### ***Why is this article important to you?***

The coronavirus disease 2019 (COVID-19) pandemic caused by infection with SARS-CoV-2 has led to more than 600,000 deaths worldwide. Patients with severe disease often experience acute respiratory distress characterized by upregulation of multiple cytokines. Immunomodulatory biological therapies are being evaluated in clinical trials for the management of the systemic inflammatory response and pulmonary complications in patients with advanced stages of COVID-19. Learners that complete this course will be able to explain the clinical pharmacology considerations in the development of immunomodulatory therapeutic proteins for mitigating the heightened inflammatory response identified in COVID-19.



### **Joint Accreditation Statement**

In support of improving patient care, the American College of Clinical Pharmacology® (ACCP) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**UAN: JA4008220-0000-20-047-H06-P**– ACPE 1 Contact Hours

**Activity Type:** Knowledge-based **Format:** Home-study **Target Audience:** 'P'

### **ACCME Designation Statement**

The Accreditation Council for Continuing Medical Education designates this Journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### **Target Audience**

Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants.

### **Learning Objectives**

After completing this activity, the learner will be able to:

1. Articulate the immunological changes in COVID-19;
2. Explain the rationale for immunomodulatory treatment;
3. Explain the current status of clinical development of immunomodulatory therapeutic proteins;
4. Learn about the clinical pharmacological considerations in investigating proteins for immunomodulation in COVID-19 treatment.

### **Requirements to Receive Credit**

In order to receive continuing education credit, the learner must register for the educational activity, study the provided journal article and complete the online learning Post-event Self-assessment, as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-event Self-Assessment and Evaluation. Contact [CE@ACCP1.org](mailto:CE@ACCP1.org) with any questions.

**Disclosures:**

Article Selection: Joseph S. Bertino Jr, PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc. Nothing to disclose.

Planner: Gouri Shankar Bhattacharyya, MD, PhD, Physician, Salt Lake City Medical Ctr. Nothing to disclose.

CE Reviewer: Vatsalya Vatsalya, MD, Research Scientist, Univ of Louisville. Nothing to disclose.

**Schedule & Fees**

JCP monthly Journal CE articles are generally released on the 1<sup>st</sup> or 2<sup>nd</sup> Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

**Acknowledgement of Financial Support**

No financial support was received for this educational activity.

**Home Study Initial Release and Expiration Dates**

**Date of Issuance:** 10/01/2020

**Expiration Date:** 12/31/2022

---

**Helpful Tips**

Download the article and access the Self-assessment Post-test, Evaluation and Certificate [here](#).

Learn how to print your CME/CPE Certificate [here](#).

---